HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults.

AbstractOBJECTIVE:
To assess the tolerability and efficacy of amodiaquine (AQ)+sulphadoxine-pyrimethamine (SP), the first-line malaria treatment in Rwanda.
METHOD:
Randomized, double-blind trial in 2003 in Kigali town. A total of 351 adult patients with uncomplicated Plasmodium falciparum malaria were randomly allocated to one of the following treatments: AQ+SP, AQ or SP. We followed patients until day 14 after treatment and recorded adverse events (AEs) and clinical and parasitological outcomes.
RESULTS:
One hundred and eighteen patients reported at least one AE: 40% in the AQ, 39% in the AQ+SP and 21% in the SP groups. The AE was classified as possibly related to the antimalarial treatment for 86 patients. The Risk Ratio for at least one AE after treatment was significantly and about fourfold higher in patients receiving AQ or AQ+SP than in patients receiving SP. Pruritus and fatigue were significantly more frequent in patients treated with AQ or AQ+SP than in those receiving SP. Severe AEs, such as fatigue, nausea, dizziness and vomiting, were observed in four patients treated with AQ, in 10 treated with AQ+SP and in one patient treated with SP.
CONCLUSION:
Amodiaquine+SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level. This renders AQ-containing regimens sub-optimal; better-tolerated treatments should be identified.
AuthorsCaterina I Fanello, Corine Karema, Walli van Doren, Claude E Rwagacondo, Umberto D'Alessandro
JournalTropical medicine & international health : TM & IH (Trop Med Int Health) Vol. 11 Issue 5 Pg. 589-96 (May 2006) ISSN: 1360-2276 [Print] England
PMID16640610 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimalarials
  • Drug Combinations
  • Amodiaquine
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Pyrimethamine
Topics
  • Adult
  • Amodiaquine (adverse effects, therapeutic use)
  • Antimalarials (adverse effects, therapeutic use)
  • Blood Cell Count
  • Double-Blind Method
  • Drug Combinations
  • Drug Therapy, Combination
  • Fatigue (chemically induced)
  • Female
  • Hematocrit
  • Humans
  • Malaria, Falciparum (blood, drug therapy, epidemiology)
  • Male
  • Neutropenia (chemically induced)
  • Pruritus (chemically induced)
  • Pyrimethamine (adverse effects, therapeutic use)
  • Rwanda (epidemiology)
  • Sulfadoxine (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: